Neuraxis price target raised to $8 from $7 at Craig-Hallum

Craig-Hallum raised the firm’s price target on Neuraxis (NRXS) to $8 from $7 and keeps a Buy rating on the shares after the company announced that they have been included in coverage from a large, national payer. This coverage expansion adds approximately 45M lives, bringing total national coverage for IBStim to nearly 100M. The Anthem win adds coverage for as much as 20% of NeurAxis’s pediatric opportunity, and the firm believes it really unlocks the opportunity itself.